US 11,965,194 B2
Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane
Jack S. Liang, South San Francisco, CA (US); Stephan Jenne, Foster City, CA (US); Emily Mundorff, Garden City, NY (US); Rama Voladri, Pleasanton, CA (US); James J. Lalonde, San Mateo, CA (US); and Gjalt W. Huisman, Redwood City, CA (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Jul. 21, 2022, as Appl. No. 17/813,950.
Application 13/110,789 is a division of application No. 12/197,286, filed on Aug. 24, 2008, granted, now 7,977,078, issued on Jul. 12, 2011.
Application 17/813,950 is a continuation of application No. 17/080,676, filed on Oct. 26, 2020, granted, now 11,427,841.
Application 17/080,676 is a continuation of application No. 16/457,396, filed on Jun. 28, 2019, granted, now 10,851,397, issued on Dec. 1, 2019.
Application 16/457,396 is a continuation of application No. 15/902,301, filed on Feb. 22, 2018, granted, now 10,385,371, issued on Aug. 20, 2019.
Application 15/902,301 is a continuation of application No. 15/184,018, filed on Jun. 16, 2016, granted, now 9,932,615, issued on Apr. 3, 2018.
Application 15/184,018 is a continuation of application No. 14/597,996, filed on Jan. 15, 2015, granted, now 9,394,552, issued on Jul. 19, 2016.
Application 14/597,996 is a continuation of application No. 13/525,048, filed on Jun. 15, 2012, granted, now 8,962,285, issued on Feb. 24, 2015.
Application 13/525,048 is a continuation of application No. 13/110,789, filed on May 18, 2011, granted, now 8,227,229, issued on Jul. 24, 2012.
Claims priority of provisional application 60/957,974, filed on Aug. 24, 2007.
Prior Publication US 2023/0068040 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 17/00 (2006.01); C12N 9/04 (2006.01); C12P 17/16 (2006.01)
CPC C12P 17/00 (2013.01) [C12N 9/0006 (2013.01); C12P 17/167 (2013.01); C12Y 101/01184 (2013.01); Y02P 20/52 (2015.11)] 19 Claims
 
1. An engineered ketoreductase polypeptide comprising an amino acid sequence that is at least 90% identical to the reference sequence SEQ ID NO:4, and wherein said amino acid sequence comprises a substitution at position 41.